The country of origin of a transfusion set
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- Accordingly, the country of origin of the transfusion set will be China.
Ruling text
In your letter dated April 22, 2025, on behalf of your client, Codan US Corporation, you requested a country of origin ruling for three medical products. The first two items were addressed in New York Ruling N355059. Additional information was provided by email dated October 22, 2025. The item under consideration is described as a transfusion set, which is a single-use sterile device intended for the intravenous infusion of blood and blood-derived products, such as packed red cells, platelets, and plasma.
It is designed to facilitate a safe and controlled transfusion procedure, including a 200-micron filter for filtration of micro-aggregates and clots. It connects to the blood bag via the spike and allows for manual flow control using clamps. The needle free valve enables injection of additional medications, and the male luer lock ensures secure connection to the patient's catheter. The set is assembled in China in a certified cleanroom.
The Chinese components include the spike with cap (plastic piercing device), transfusion chamber (chamber with 200 micro filter), roller clamp (flow rate controller), slide clamp (flow on/off control), and the male luer lock (connector to patient catheter). The needle free valve can be made in Poland or China. The primary PVC tubing (2160mm medical grade tubing) is made in South Korea.
The manufacturing process starts with bonding the 2160mm PVC tubing with the spike, transfusion chamber, needle free valve, and luer connector using cyclohexanone solvent. Next, the roller and slide clamps are added to the main tubing. Finally, leak testing, packaging and ethylene oxide sterilization occurs. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).
Regarding the country of origin of the transfusion set, it is our opinion that the assembly process performed in China is not complex and does not constitute a substantial transformation. The process predominantly involves a simple combining of the various components. The combining of these parts in China does not create a new and different article of commerce with a name, character, and use distinct from the individual components.
Therefore, to determine the country of origin of the transfusion set, we rely on the origin of the transfusion chamber, which provides the essential function of the set. It is the transfusion chamber from China that allows for the safe passage of the red cells, plasma, and platelets without clots or micro-aggregates. While the tubing is also important, we find the filter performs the vital function. Accordingly, the country of origin of the transfusion set will be China.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N355466).